e-ULTIMASTER Trial
2
neutrals-100
One of the largest, prospective worldwide registries
neutrals-100
Featured products: Ultimaster™ Tansei™ Sirolimus Eluting Coronary Stent System, Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System
neutrals-100
true
ComplexPCI
Complex PCI
Bifurcationlesions
Bifurcation lesions
Multivesseldisease
Multivessel disease
HighriskACS
High risk ACS
CTO
CTO
Low TLF rate at 1 year in a global all-comers population.
section-id
Background
Complex PCI
3
neutrals-100
  • e-ULTIMASTER all-comer registry enrolled more than 10,000 patients meeting complex PCI criteria
  • Complex PCI was defined as multivessel PCI, ≥ 3 stents implanted, ≥ 3 lesions treated, bifurcation PCI with ≥ 2 stents, total stent length> 60mm and chronic total occlusion
  • Although complex, PCI had a higher risk of ischemic and bleeding event, overall event rates for both the complex and the non-complex groups at 1 year were low
neutrals-100
Mohamed et al. EuroIntervention 2020;16:603-612
section-id
ComplexPCI
Bifurcation lesions
3
neutrals-100
  • 4,395 patients with bifurcation lesions treated with Ultimaster DES showed excellent clinical outcomes with TLF of 5.1% at 1 year
  • Use of the proximal optimization technique (POT) was associated with a better clinical outcome with respect to TLF and TVF at 1 year due to a strong impact on the risk of TV-MI, stent thrombosis and revascularizations
neutrals-100
false
e-ULTIMASTER bifurcation subgroup: propensity-matched clinical outcomes at 1 year
5
neutrals-100
section-id
Bifurcationlesions
Multivessel disease
3
neutrals-100
  • The revascularization strategy (complete versus incomplete revascularization) in multivessel disease patients treated with Ultimaster DES was assessed at 1-year follow-up
  • Complete revascularization was associated with better relief from angina, lower mortality, less target vessel failure (TVF), and lower patient oriented composite endpoint (POCE)
  • Ultimaster DES demonstrated excellent results in this complex population
neutrals-100
section-id
Multivesseldisease
High risk ACS
3
neutrals-100
  • The 1-year results of 14,874 STEMI or NSTEMI patients treated with Ultimaster stent showed a higher risk of cardiac death and stent thrombosis in this high hisk ACS group
  • However, the clinical outcomes in both high risk ACS and the rest of the patient group were very good
neutrals-100
e-ULTIMASTER High risk ACS subgroup: Clinical outcomes at 1 year
5
neutrals-100
section-id
HighriskACS
CTO
3
neutrals-100
  • 1722 patients were treated for CTO with mean age (SD) of 63.8 (10.7) years
  • Patients in the CTO group had a higher prevalence of comorbidities
  • At 1 year, favourable clinical outcomes were observed with Ultimaster, with low incidences of cardiac death, TV-related MI, CD-TLR, and stent thrombosis
neutrals-100
e-ULTIMASTER CTO subgroup: Clinical outcomes at 1 year
5
neutrals-100
section-id
CTO
Featured products
3
neutrals-100
default-carousel
default-carousel
Ultimaster™ Tansei™
Sirolimus Eluting Coronary Stent System
/content/terumo-europe-ia/en/interventional-systems/products/product-type/stents/ultimaster-tansei-sirolimus-eluting-coronary-stent-system
default-carousel
Ultimaster™ Nagomi™
Sirolimus Eluting Coronary Stent System
/content/terumo-europe-ia/en/interventional-systems/products/product-type/stents/ultimaster-nagomi-sirolimus-eluting-coronary-stent-system